Figure 7.
Effect of silencing AKT and ERBB2 pathways on in vivo efficacy of docetaxel. Mice were purchased from Razi Research Institute, Tehran, Iran. Approximately 106 4T1 cells were inoculated subcutaneously on the mammary pad of mice. Based on tumor volume calculations, mice were randomized and treated intravenously through tail-vein injection on day 10 and 13. The therapeutics included 100 μL of carbonate apatite entailing 4 μL of 1M CaCl2 and 50 nM of AKT and ERBB2 siRNA plus 1mg/kg Doc. Body weight and tumor outgrowth were monitored every other day. Data is represented as mean ± SD, n = 6 and values are significant when * p value < 0.05 for CA/Doc/AKT/ERBB2 vs CA/Doc, # p value < 0.05 for CA/ERBB2 compared to CA and ** p value < 0.05 for Ca/Doc against Doc.